MANILA, Philippines, April 24, 2025 /PRNewswire/ -- SWS Medical, a leading Chinese blood purification provider, is excited to participate in the 45th Philippine Society of Nephrology Annual Convention (April 24-26, 2025 Preferred Booth 1), the Philippines' largest nephrology academic event. In partnership with Hemotek Renal Center, Inc., a subsidiary of Euro-Med Laboratories Phil., Inc. and the country's fastest-growing hemodialysis chain with 21 centers and over 500 dialysis machines, SWS is committed to advancing kidney health.
For over two decades, SWS has cemented itself as a key player in dialysis, exporting to over 80 countries and securing 200 patents. In China, it leads domestic brands with a market share of 15.9% in 2024, rising to 27.11% in February 2025.
SWS has experienced impressive growth within ASEAN, installing thousands of machines in key markets including Indonesia, Thailand, Malaysia, and the Philippines. In Indonesia alone, installations have surpassed 1,000 units, solidifying SWS's position as the leading dialysis supplier in the nation. Furthermore, SWS has trained over 200 engineering and clinical teams, supporting the WHO's 2030 CKD treatment goals. Dr. Sonny L. Antonio, FPCP, FPSN, COO of Hemotek stated: "We are excited about this partnership with SWS as it expands our services not only to patients receiving hemodialysis but also to healthcare institutions, by providing reliable hemodialysis machines and safe, high-quality, and cost-effective consumables that support optimal treatment outcomes."
Since 2014, SWS's 4000 series hemodialysis machines have become popular in the Philippines for their user-friendly interface, reliability, compatibility with various consumables, and customizable therapy profiles.
At the event, SWS will highlight its latest SWS-6000 series dialysis machines, distributed by Hemotek. This advanced machine, China's best-seller, offers intelligent interaction and real-time monitoring of key parameters like blood pressure, temperature, volume, and urea clearance.
The TWT-EF210 dialysis fluid filter will also be showcased. Using advanced steam sterilization, this filter enhances molecular clearance and biocompatibility with a stable PES membrane and patented design, optimized through A.S.M technology for effective renal therapy.
Based in Chongqing, SWS Medical is a prominent global provider of innovative medical products and services. Its offerings include blood purification devices, disposables, dialysis management system, and a network of dialysis centers. Publicly traded on the China STAR Market (SSE: 688410), its devices hold CE markings and comply with ISO 13485:2016 standards.
swsdialysis.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
SWS Medical and Hemotek - Partners in Innovations at the 45th Philippine Society of Nephrology Annual Convention
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
